{
    "symbol": "PFE",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-01 16:06:04",
    "content": " In addition to generating a stellar financial performance, since our last earnings call, we reported positive pivotal data for several exciting pipeline programs, including our RSV vaccine candidate for older adults, Prevnar 20 for children, the potential combination of treatment of TALZENNA and XTANDI in men with metastatic castration-resistant prostate cancer, our pentavalent meningococcal vaccine candidate for adolescents and young adults, as well as exciting progress for our GLP-1 program in type 2 diabetes and obesity. On the December 12, what you should expect, it is a good overview of our very important new product launches in the coming 18 months, with more details about the science and the market potential of those launches as well as some of the most important pipeline potential new medicines and vaccines, that they are not going to be launched in the next 18 months but will be launched in the period between '24 and '30. Thank you very much. Thank you very much. Thank you very much. Thank you very much. Thank you very much."
}